Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 35
Peru obesity drugs: budget impact explained
A 2026 analysis of 76,819 Peruvians found that full obesity drug coverage could cost up to S/143 billion per year. Here is what the numbers mean.
Oral GLP-1 drugs for obesity, no diabetes
A 2026 network meta-analysis of nine trials ranks oral semaglutide and orforglipron as top performers for weight loss in adults with obesity without diabetes.
Retatrutide: US compassionate use explained
Retatrutide is investigational. The US has opened a compassionate use pathway after Trump speculation. Here is what that means and who may qualify.
Semaglutide and medication-overuse headache
Could GLP-1 agonists like semaglutide address the addiction-like behaviour behind medication-overuse headache? A 2026 editorial examines the hypothesis.
Semaglutide kidney outcomes: pooled trials
A prespecified pooled analysis of 30,787 participants finds semaglutide cuts serious kidney events by 16% (HR 0.84) vs placebo.
SGLT2 inhibitor ketoacidosis in the ICU
Two ICU cases show SGLT2 inhibitor ketoacidosis after cardiac surgery and GLP-1 co-prescription. Normal glucose levels masked the diagnosis in both patients.
Zepbound versus obesity pills
Zepbound still has strong direct trial evidence as oral obesity medicines add useful, but not automatically superior, options.
What a high IGF-1 result means
A high or high-normal IGF-1 result does not make tesamorelin safer. Here is what the label, human trials, and evidence gaps actually say.
Peptides for sleep and recovery: a primer
Ipamorelin and CJC-1295 act on the GH axis that drives slow-wave sleep. Here is what the research shows and where it runs out.
Peptides for tendon and ligament recovery
BPC-157 and TB-500 are the peptides most linked to tendon recovery. The animal data is promising; the human data is thin.
Semax and alcohol cravings: the evidence
No human study shows that Semax reduces alcohol cravings, and one quoted animal result cannot answer a personal safety question.
Tirzepatide and heart events: BMJ study
A 2026 BMJ cohort linked tirzepatide to fewer cardiovascular events than sitagliptin, but the result remains observational.